Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bright Green Corp BGXX

Healthcare
Bright Green Corporation is a producer and manufacturer of plant-based drugs and active pharmaceutical ingredients (APIs). The Company specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. It plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). It also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, It also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. It is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. It also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.


NDAQ:BGXX - Post by User

Bright Green Corp > Volume
<< Previous
 Bullboard Posts
User Avatar Image
(29)
•••
Comment by gunner1324on Apr 04, 2023 6:28pm
62 Views
Post# 35379845

RE:Volume

RE:VolumeJohn Stockwell and friends so they can short it down
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities